

Atripla[®] (EFV/FTC/TDF) Storage and Stability

This document is in response to your request for extended storage and stability information of Atripla[®] (efavirenz/emtricitabine/tenofovir disoproxil fumarate [EFV/FTC/TDF]) 600/200/300 mg tablets and does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of storing or administering any drug in a manner inconsistent with its approved labeling. Atripla[®] (EFV/FTC/TDF) should be stored according to the product label.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/atripla/atripla_pi.

Product Labeling¹

EFV/FTC/TDF tablets are packaged in bottles containing 30 tablets with a silica gel desiccant and is closed with a child-resistant closure. Store at 25°C (77°F); excursions permitted from 15°C to 30°C (59–86°F). Keep container tightly closed. Dispense only in original container.

Alternative Storage and Stability Information²

The table below summarizes available data from in-house studies regarding the storage of EFV/FTC/TDF tablets in varying conditions. The “acceptable duration” refers to the stability of EFV/FTC/TDF tablets in the specified packaging and storage condition, but it does not endorse alternative packaging or use beyond the expiration date stated on the original packaging.

Table 1. Summary of Extended Stability Data for EFV/FTC/TDF Tablets²

Storage Condition	Package Type	Acceptable Duration
40°C (104°F)/75% RH	Original sealed bottle	6 months
50°C (122°F)	Original sealed bottle	1 month
25°C (77°F)/80% RH	Original sealed bottle	3 months
5°C (41°F)	Original sealed bottle	2 months
-20°C (-4°F)	Original sealed bottle	4 weeks
Open dish, 25°C (77°F)/60% RH	Open petri dish	4 weeks

Abbreviation: RH=relative humidity.

References

1. Enclosed, Gilead Sciences Inc. ATRIPLA[®] (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.
2. Gilead Sciences Inc. Data on File.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Atripla US Prescribing Information available at:

www.gilead.com/-/media/files/pdfs/medicines/hiv/atripla/atripla_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

ATRIPLA, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.